Category - Developments

Developments

Day One acquires Mersana and expands pipeline

Day One Biopharmaceuticals (NASDAQ: DAWN) has announced the completion of all conditions of its tender offer to acquire all outstanding shares of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus one...

January 7, 2026

Developments

Actuate announces positive Phase 1 elraglusib results in pediatric cancer

Actuate Therapeutics (NASDAQ: ACTU) has announced results from the phase 1 portion of its Actuate-1902 Phase 1/2 clinical study evaluating elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus...

January 7, 2026

Developments

YD Bio enters MOU to merge with EG BioMed

YD Bio (NASDAQ: YDES) has announced that it has entered into a Memorandum of Understanding (MOU) to merge with closely held EG BioMed—a biotechnology company specializing in DNA methylation–based cancer diagnostics and...

January 7, 2026

Developments

First patient dosed in Akebia’s Phase 2 trial of praliciguat in FSGS

Akebia Therapeutics (NASDAQ: AKBA) has announced that the first patient has been dosed in its Phase 2 clinical trial of praliciguat, an oral once-daily soluble guanylate cyclase stimulator being evaluated for the...

January 7, 2026

Developments

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company’s TULSA-PRO system. The milestone marks the...

January 6, 2026

Developments

Polyrizon reports positive preclinical results of PL-14 vs HPMC

Polyrizon (NASDAQ: PLRZ) has announced new results from a preclinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an...

January 5, 2026

Developments

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual...

January 5, 2026

Developments

Hoth expands IP portfolio with filing of two patent applications

Hoth Therapeutics (NASDAQ: HOTH) has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin...

January 5, 2026

Developments

Annovis launches OLE study in Parkinson’s disease

Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients. The study aims...

December 19, 2025

Developments

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

Altimmune (NASDAQ: ALT) has announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated...

December 19, 2025

Category - Developments

Subscribe